NCT05442788 - A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 2, 2021

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions

Plaque Psoriasis

Interventions

BIOLOGICAL

HB0017 150mg or matching placebo

Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.

BIOLOGICAL

HB0017 300mg or matching placebo

Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.

BIOLOGICAL

HB0017 450mg or matching placebo

Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.

Trial Locations (1)

The First Affiliated Hospital of Bengbu Medical College, Bengbu